| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Caspase-3 Bcl-2 Bcl-xL
|
|---|---|
| ln Vitro |
Anticancer agent 201 (Compound 2f) (3.5 μM, 17.5 μM; 24 hours) can significantly induce cytotoxicity, increase the number of apoptotic cells, and cause a dose-dependent decrease in the mitochondrial membrane potential of CCRF-CEM cells[1]. Anticancer agent 201 (3.5 μM, 17.5 μM; 24 hours) blocks or slows down the cell cycle in the G0/G1 phase, reduces the proportion of cells in the S phase, and inhibits RNA synthesis in CCRF-CEM cells[1]. Cytotoxic activity of anticancer agent 201 against 8 tumor (including multidrug-resistant variants) and 2 normal fibroblast cell lines[1] Cell lines CCRF-CEM CEM-DNR K562 K562-TAX A549 HCT116 HCT116p53-/- U20S BJ MRC-5 IC50 (μM) 3.5 4.9 23 17 11 10 18 19 ＞50 27 Apoptosis Analysis[1] Cell Line: CCRF-CEM cancer cell line Concentration: 3.5 μM, 17.5 μM Incubation Time: 24h Result: Induced the strongest cytotoxic reaction and the number of apoptotic cells increased significantly. Resulted in a significant decrease in mitochondrial membrane potential of CCRF-CEM cells in a dose-dependent manner. Cell Cycle Analysis[1] Cell Line: CCRF-CEM cancer cell line Concentration: 3.5 μM, 17.5 μM Incubation Time: 24h Result: Caused the cell cycle to be blocked or slowed down in the G0/G1 phase, while the proportion of S phase cells decreases. At 17.5 μM, the mitosis rate of the cells decreased. At 3.5 μM increased the proportion of BRDU-positive cells. At 17.5μM, the proportion of BRDU- positive cells decreased. At 17.5μM, RNA synthesis almost completely stopped.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: CCRF-CEM cancer cell line Concentration: 3.5 μM, 17.5 μM Incubation Duration: 24h Experimental Results: Leaded to decreased expression of both Bcl-2 and Bcl-XL. At 17.5μM, caused the activation of caspase-3 and the cleavage of PARP. |
| References |
| Molecular Formula |
C34H49F3O4
|
|---|---|
| Molecular Weight |
578.75
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7279 mL | 8.6393 mL | 17.2786 mL | |
| 5 mM | 0.3456 mL | 1.7279 mL | 3.4557 mL | |
| 10 mM | 0.1728 mL | 0.8639 mL | 1.7279 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
